血清miR-21和miR-423-5p对心脏瓣膜病伴有心力衰竭患者的诊断价值

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (939 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨血清miR-21和miR-423-5p对心脏瓣膜病（VHD）引起心力衰竭的潜在诊断价值。方法选择2014年8月~2016年4月上海交通大学医学院附属第九人民医院心内科收治的伴心力衰竭的VHD患者60例为VHD组，选择同期正常人60名为对照组。通过实时荧光定量PCR（qRT-PCR）检测VHD伴有心力衰竭患者和正常人的血清miR-21和miR-423-5p表达，并利用ROC曲线分析miR-21和miR-423-5p作为VHD伴有心力衰竭诊断和预后生物标志物的临床价值。结果 VHD组患者血清miR-21和miR-423-5p表达明显高于对照组，差异有统计学意义（P < 0.05）。伴有肺动脉高压（PH）的VHD患者血清miR-423-5p水平高于PH的VHD患者，差异有统计学意义（P < 0.05）。ROC曲线结果显示，血清miR-21和miR-423-5p可以作为VHD伴心力衰竭的诊断标志物。结论血清miR-21和miR-423-5p具备诊断VHD伴有心力衰竭的临床价值。血清miR-423-5p可作为VHD伴有心力衰竭的诊断标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李玉梅1 盛红彬2 徐恒仕1

关键词 ： miRNA, miR-423-5p, 心瓣膜病, 心力衰竭, 肺动脉高压, ROC曲线

Abstract：Objective To investigate the potential diagnostic value of serum miR-21 and miR-423-5p for heart failure (HF) due to heart valve disease (VHD). Methods From August 2014 to April 2016, in Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, 60 VHD patients with HF were selected as VHD group, at the same period, 60 healthy persons were selected as control group. The levels of serum miR-21 and miR-423-5p were measured by qRT-PCR. The ROC curve was used analyse the clinical Value of miR-21 and miR-423-5p as VHD with biomarkers for diagnosis and prognosis of heart failure. Results The levels of miR-21 and miR-423-5p in sera of patients in VHD group were higher than control group, the differences were statistically significant (P < 0.05). The levels of miR-423-5p in sera of VHD patients with pulmonary hypertension (PH) were higher than VHD patients without PH, the differences were statistically significant (P < 0.05). ROC curve result showed that serum miR-21 and miR-423-5p had potential diagnostic values on HF due to VHD. Conclusion Serum miR-21 and miR-423-5p show potential diagnostic values on HF due to VHD. Moreover, serum miR-423-5p can be an effective biomarker for diagnosing VHD patients with PH.

Key words： MiRNA MiR-423-5p Valvular heart disease Heart failure Pulmonary hypertension ROC curve

基金资助:上海市公共卫生重点学科建设项目（15GWZK0 501）。

通讯作者: 盛红彬（1975.1-），男，硕士，副主任药师，主要从事医院管理和药事管理研究。

引用本文:

李玉梅1 盛红彬2 徐恒仕1. 血清miR-21和miR-423-5p对心脏瓣膜病伴有心力衰竭患者的诊断价值[J]. 中国医药导报, 2018, 15(33): 151-154,162.
LI Yumei1 SHENG Hongbin2 XU Hengshi1. Diagnostic values of miR-21 and miR-423-5p in patients with valvular heart disease and heart failure. 中国医药导报, 2018, 15(33): 151-154,162.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I33/151

[1] Rogers C，Bush N. Heart failure：pathophysiology，diagnosis，medical treatment guidelines，and nursing management [J]. Nurs Clin North Am，2015，50（4）：787-799.
[2] Don-Wauchope AC，McKelvie RS. Evidence based application of BNP/NT-proBNP testing in heart failure [J]. Clin Biochem，2015，48（4-5）：236-246.
[3] Omar HR，Guglin M. A single BNP measurement in acute heart failure does not reflect the degree of congestion [J]. J Crit Care，2016，33：262-265.
[4] Murach KA，McCarthy JJ. MicroRNAs，heart failure，and aging：potential interactions with skeletal muscle [J]. Heart Fail Rev，2017，22（2）：209-218.
[5] Souza RW，Fernandez GJ，Cunha JP，et al. Regulation of cardiac microRNAs induced by aerobic exercise training during heart failure [J]. Am J Physiol Heart Circ Physiol，2015，309（10）：H1629-1641.
[6] Vegter EL，Peter VDM，De Windt LJ，et al. MicroRNAs in heart failure：from biomarker to target for therapy [J]. Eur J Heart Fail，2016，18（5）：457-468.
[7] Hulanicka M，Garncarz M，Parzeniecka-Jaworska M，et al. Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds [J]. BMC Vet Res，2014，10（1）：205.
[8] Thome JG，Mendoza MR，Cheuiche AV，et al. Circulating microRNAs in obese and lean heart failure patients：A case-control study with computational target prediction analysis [J]. Gene，2015，574（1）：1-10.
[9] Bjork JB，Alton KK，Georgiopoulou VV，et al. Defining Advanced Heart Failure：A Systematic Review of Criteria Used in Clinical Trials [J]. J Card Fail，2016，22（7）：569-577.
[10] Simonneau G，Gatzoulis MA，Adatia I，et al. Updated clinical classification of pulmonary hypertension [J]. J Am Coll Cardiol 2013，62（25 Suppl）：D34-D41.
[11] Livak KJ，Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△CT Method [J]. Methods，2001，25（4）：402-408.
[12] Brown JN，Brewer HM，Nicora CD，et al. Protein and microRNA biomarkers from lavage，urine，and serum in military personnel evaluated for dyspnea [J]. BMC Med Genomics，2014，7：58.
[13] Oliveiracarvalho V，Silva MMFD，Guimar?觔es GV，et al. MicroRNAs：new players in heart failure [J]. Mol Biol Rep，2013，40（3）：2663-2670.
[14] Min PK，Chan SY. The biology of circulating microRNAs in cardiovascular disease [J]. Eur J Clin Invest，2015，45（8）：860-874.
[15] Dong S，Ma W，Hao B，et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2 [J]. Int J Clin Exp Pathol，2014，7（2）：565-574.
[16] Kolpa HJ，Peal DS，Lynch SN，et al. miR-21 represses Pdcd4 during cardiac valvulogenesis [J]. Development，2013， 140（10）：2172-2180.
[17] Gundara JS，Zhao J，Gill AJ，et al. Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer [J]. Cancer Med，2015，4（2）：174-182.
[18] Breitling S，Ravindran K，Goldenberg NM，et al. The pathophysiology of pulmonary hypertension in left heart disease [J]. Am J Physiol Lung Cell Mol Physiol，2015，309（9）：L924-941.
[19] Malhotra R，Dhakal BP，Eisman AS，et al. Pulmonary vascular distensibility predicts pulmonary hypertension severity，exercise capacity，and survival in heart failure [J]. Circ Heart Fail，2016，9（6）：e003-011.
[20] Wei C，Li L，Kim IK，et al. NF-kappaB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress [J]. Free Radic Res，2014，48（3）：282-291.